Saliva and serum levetiracetam concentrations in patients with epilepsy

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 313-318

  Mecarelli, Oriano ^a,c   Voti, Pietro Li ^a   Pro, Stefano ^a   Romolo, Francesco Saverio ^a   Rotolo, Maria ^a   Pulitano, Patrizia ^a   Accornero, Neri ^a   Vanacore, Nicola ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Levetiracetam; Saliva; Serum; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; ENZYME INDUCING AGENT; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PIRACETAM;

ACCURACY; ADD ON THERAPY; ADULT; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; AGED; BLOOD; CHEMISTRY; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; SALIVA; STATISTICAL MODEL;

ADULT; AGED; ANTICONVULSANTS; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PIRACETAM; SALIVA;

EID: 34447510947     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3180683d55     Document Type: Article

References (24)

1. Troupin AS, Friel P. Anticonvulsant level in saliva, serum and cerebrospinal fluid. Epilepsia. 1975;16:223-227.
2. McAuliffe JJ, Shervin AL, Leppik IE, et al. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology. 1977;27:409-413.
3. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva: an update. Clin Pharmacokinet. 1992;23:365-379.
4. Gorodischer R, Burtin P, Hwang P, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patients and parental preferences and an economic analysis. Ther Drug Monit. 1994;16:437-443.
5. Liu H, Delgato MR. Therapeutic drug concentration monitoring using saliva samples. Clin Pharmacokinet. 1999;36:453-470.
6. Grim SA, Ryan M, Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003;25:61-66.
7. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol. 1986;31:91-94.
8. Tsiropoulos I, Kristensen O, Klitgaard NA. Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit. 2000;22:517-521.
9. Miles MV, Tang PH, Glauser TA, et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003;29:143-147.
10. Jones MD, Ryan M, Miles MV, et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit. 2005;27:576-579.
11. Tennison M, Ali I, Miles MV, et al. Feasibility and acceptance of salivary monitoring of antiepileptic drugs via US Postal Service. Ther Drug Monit. 2004;26:295-299.
12. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicentre, double-blind, responder selected study evaluating monotherapy. Epilepsia. 2000;41:1276-1283.
13. Cereghino JJ, Biton V, Abou-Khalil B, et al., and the United States Levetiracetam Study Group. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
14. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46(Suppl 9):154-160.
15. Hermann S, Wang-Tilz Y, Pauli E, et al. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). Epilepsia. 2006;47:516-522.
16. 2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861-9866.
17. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77-85.
18. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy society. Epilepsia. 2004;45:410-423.
19. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53:47-56.
20. May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690-699.
21. Contin M, Albani F, Riva R, et al. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2004;26:375-379.
22. Gidal BE, Baltes E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 2005;64:1-11.
23. Hold KM, de Boer D, Zuidema J, et al. Saliva as an analytical tool in toxicology. Intern J Drug Test. 1996;1:1-36.
24. Samyn N, Verstraete A, van Haeren C, et al. Analysis of drugs of abuse in saliva. Forensic Sci Rev. 1999;11:1-19.